{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:13:18Z","timestamp":1792181598394,"version":"4.4.0"},"reference-count":123,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2018,7,31]],"date-time":"2018-07-31T00:00:00Z","timestamp":1532995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoF"],"abstract":"<jats:p>Despite the recent introduction of mold-active agents (posaconazole and isavuconazole), in addition to amphotericin B products, to our armamentarium against mucormycosis, many uncertainties remain for the management of this uncommon opportunistic infection, as there are no data from prospective randomized clinical trials to guide therapy. In this mini-review, we present the current status of treatment options. In view of the heterogeneity of the disease (different types of affected hosts, sites of infection, and infecting Mucorales), mucormycosis management requires an individualized management plan that takes into account the net state of immunosuppression of the host, including comorbidities, certainty of diagnosis, site of infection, and antifungal pharmacological properties.<\/jats:p>","DOI":"10.3390\/jof4030090","type":"journal-article","created":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T03:10:01Z","timestamp":1533093001000},"page":"90","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":161,"title":["Therapy of Mucormycosis"],"prefix":"10.3390","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6955-3453","authenticated-orcid":false,"given":"Nikolaos V.","family":"Sipsas","sequence":"first","affiliation":[{"name":"Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria N.","family":"Gamaletsou","sequence":"additional","affiliation":[{"name":"Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Anastasopoulou","sequence":"additional","affiliation":[{"name":"Pathophysiology Department, Medical School, National and Kapodistrian University of Athens, Mikras Asias 75, 115 27 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,7,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1093\/cid\/cir864","article-title":"Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: Molecular mycologic perspectives","volume":"54","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1086\/432579","article-title":"Epidemiology and outcome of zygomycosis: A review of 929 reported cases","volume":"41","author":"Roden","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1128\/CMR.00056-10","article-title":"Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species","volume":"24","author":"Gomes","year":"2011","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1128\/CMR.13.2.236","article-title":"Zygomycetes in human disease","volume":"13","author":"Ribes","year":"2000","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0140-6736(05)71046-1","article-title":"Multifocal cutaneous mucormycosis complicating polymicrobial wound infections in a tsunami survivor from Sri Lanka","volume":"365","author":"Andresen","year":"2005","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JOM.0b013e31803b94f9","article-title":"Implications of detecting the mold Syncephalastrum in clinical specimens of New Orleans residents after hurricanes Katrina and Rita","volume":"49","author":"Rao","year":"2007","journal-title":"J. Occup. Environ. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1056\/NEJMoa1204781","article-title":"Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011","volume":"367","author":"Benedict","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ki.1994.89","article-title":"Deferoxamine augments growth and pathogenicity of Rhizopus, while hydroxypyridinone chelators have no effect","volume":"45","author":"Boelaert","year":"1994","journal-title":"Kidney Int."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/0006-2952(94)90314-X","article-title":"Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus","volume":"47","author":"Boelaert","year":"1994","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0272-6386(12)80606-8","article-title":"Deferoxamine therapy and mucormycosis in dialysis patients: Report of an international registry","volume":"18","author":"Boelaert","year":"1991","journal-title":"Am. J. Kidney Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/sj.bmt.1701885","article-title":"Mucormycosis in allogeneic bone marrow transplant recipients: Report of five cases and review of the role of iron overload in the pathogenesis","volume":"24","author":"Maertens","year":"1999","journal-title":"Bone Marrow Transplant."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/MD.0000000000000221","article-title":"Posttraumatic mucormycosis: A nationwide study in France and review of the literature","volume":"93","author":"Lelievre","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/cid\/ciw563","article-title":"Detection of circulating Mucorales DNA in critically ill burn patients: Preliminary report of a screening strategy for early diagnosis and treatment","volume":"63","author":"Legrand","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.arcmed.2006.06.009","article-title":"Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center","volume":"38","author":"Sims","year":"2007","journal-title":"Arch. Med. Res."},{"key":"ref_15","first-page":"155","article-title":"Cutaneous mucormycosis","volume":"11","author":"Skiada","year":"2013","journal-title":"Skinmed"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/eci.12467","article-title":"Healthcare-associated outbreaks due to mucorales and other uncommon fungi","volume":"45","author":"Davoudi","year":"2015","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/cid\/cis749","article-title":"Invasive mold infections following combat-related injuries","volume":"55","author":"Warkentien","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1212\/WNL.0b013e318203e92b","article-title":"Pearls & oy-sters: Isolated cerebral zygomycosis in an intravenous drug user","volume":"76","author":"Clark","year":"2011","journal-title":"Neurology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/j.1469-0691.2010.03456.x","article-title":"Zygomycosis in Europe: Analysis of 230 cases accrued by the registry of the European Confederation of MedicalMycology (ECMM) working Group on Zygomycosis between 2005 and 2007","volume":"17","author":"Skiada","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Zilberberg, M.D., Shorr, A.F., Huang, H., Chaudhari, P., Paly, V.F., and Menzin, J. (2014). Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: A retrospective analysis of US hospital discharge data. BMC Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-310"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/clinids\/17.5.881","article-title":"Invasive infection due to Apophysomyces elegans in immunocompetent hosts","volume":"17","author":"Weinberg","year":"1993","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/j.bjps.2008.04.040","article-title":"Cutaneous mucormycosis: Report of five cases and review of the literature","volume":"62","year":"2009","journal-title":"J. Plast. Reconstr. Aesthet. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopooietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12371","article-title":"ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013","volume":"20","author":"Cornely","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/cir868","article-title":"Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary and disseminated mucormycosis (zygomycosis)","volume":"54","author":"Walsh","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/590004","article-title":"Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis","volume":"47","author":"Chamilos","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: A single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1128\/AAC.00004-15","article-title":"Etest cannot be recommended for in vitro susceptibility testing of Mucorales","volume":"59","author":"Caramalho","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11908-012-0272-6","article-title":"Rhino-orbital-cerebral mucormycosis","volume":"14","author":"Gamaletsou","year":"2012","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jac\/dkg020","article-title":"In vitro susceptibilities of zygomycetes to conventional and new antifungals","volume":"51","author":"Dannaoui","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1128\/JCM.00318-16","article-title":"Role of antifungal susceptibility testing in non-Aspergillus invasive mold infections","volume":"54","author":"Lamoth","year":"2016","journal-title":"J. Clin. Microbiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1086\/516353","article-title":"Amphotericin B lipid complex for invasive fungal infections: Analysis of safety and efficacy in 556 cases","volume":"26","author":"Walsh","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/13693780903311944","article-title":"Primary treatment of mucormycosis with liposomal amphotericin B: Analysis of 28 cases","volume":"48","author":"Shoham","year":"2010","journal-title":"Med. Mycol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/AAC.04435-14","article-title":"Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales","volume":"59","author":"Chakrabarti","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/AAC.01222-09","article-title":"Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis","volume":"54","author":"Lewis","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1182\/blood-2011-03-316430","article-title":"How I treat mucormycosis","volume":"118","author":"Kontoyiannis","year":"2011","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1093\/jac\/dkv236","article-title":"Prospective pilot study of high-dose (10 mg\/kg\/day) liposomal amphotericin b (L-AMB) for the initial treatment of mucormycosis","volume":"70","author":"Lanternier","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: Posaconazole: A broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1128\/AAC.03569-14","article-title":"Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis","volume":"58","author":"Lewis","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1128\/AAC.47.11.3647-3650.2003","article-title":"Activity of posaconazole in treatment of experimental disseminated mucormycosis","volume":"47","author":"Dannaoui","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1128\/AAC.01583-15","article-title":"Effect of preexposure to triazoles on susceptibility and virulence of Rhizopus oryzae","volume":"59","author":"Bellanger","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1097\/01.tp.0000168343.47569.1c","article-title":"Pulmonary mucormycosis (mucormycosis) in a lung transplant recipient: Recovery after posaconazole therapy","volume":"80","author":"Brugiere","year":"2005","journal-title":"Transplantation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.jinf.2004.11.002","article-title":"Absidia posttraumatic infection: Successful treatment with posaconazole","volume":"51","author":"Garbino","year":"2005","journal-title":"J. Infect."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1128\/AAC.50.1.126-133.2006","article-title":"Posaconazole as salvage therapy for zygomycosis","volume":"50","author":"Greenberg","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1086\/500212","article-title":"Posaconazole is effective as salvage therapy in zygomycosis: A retrospective summary of 91 cases","volume":"42","author":"Hare","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: Exposure-response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dks268","article-title":"A new solid oral tablet formulation of posaconazole: A randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers","volume":"67","author":"Krishna","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6993","DOI":"10.1128\/AAC.04035-14","article-title":"Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity","volume":"58","author":"Jung","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1093\/jac\/dkx263","article-title":"Pharmacokinetics and safety results from the phase 3 randomized, open-label, study of intravenous posaconazole in patients at risk of invasive fungal disease","volume":"72","author":"Cornely","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_53","unstructured":"Astellas Pharma US (2018, July 01). Prescribing Information for Isavuconazonium Sulfate. Available online: https:\/\/www.astellas.us\/docs\/cresemba.pdf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/cpdd.284","article-title":"Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults","volume":"6","author":"Groll","year":"2017","journal-title":"Clin. Pharmacol. Drug. Dev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: A new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Kontoyiannis","year":"2015","journal-title":"Future Microbiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1517\/14656566.2015.1057500","article-title":"The \u2018cephalosporin era\u2019 of triazole therapy: Isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections","volume":"16","author":"Chitasombat","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/cid\/civ571","article-title":"Isavuconazole: A new broad-spectrum triazole antifungal agent","volume":"61","author":"Miceli","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e12712","DOI":"10.1111\/tid.12712","article-title":"Use of isavuconazole in a patient with voriconazole- induced QTc prolongation","volume":"19","author":"Trang","year":"2017","journal-title":"Transpl. Infect. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1128\/AAC.01919-15","article-title":"In Vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order","volume":"59","author":"Arendrup","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1128\/AAC.02301-13","article-title":"Isavuconazole therapy protects immunosuppressed mice from mucormycosis","volume":"58","author":"Luo","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1128\/JCM.03176-13","article-title":"Isavuconazole treatment of a patient with disseminated mucormycosis","volume":"52","author":"Peixoto","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s15010-013-0552-6","article-title":"Successful isavuconazole salvage therapy in a patient with invasive mucormycosis","volume":"42","author":"Ervens","year":"2014","journal-title":"Infection"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.mmcr.2016.03.002","article-title":"Isavuconazole as salvage therapy for mucormycosis","volume":"11","author":"Graves","year":"2016","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jac\/dkp430","article-title":"Forty-one recent cases of invasive zygomycosis from a global clinical registry","volume":"65","author":"Heinz","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Rausch, C.R., DiPippo, A.J., Bose, P., and Kontoyiannis, D.P. (2018). Breakthrough fungal infections in leukemia patients receiving isavuconazole. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciy406"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Fung, M., Stuartz, B.S., Doernberg, S.B., Langelier, C., Lo, M., Graff, L., Tan, M., Logan, A.C., Chin-Hong, P., and Babik, J.M. (2018). Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: What is happening in the real world setting?. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciy260"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1128\/AAC.04569-14","article-title":"Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: Results of a phase 2, dose escalation study","volume":"59","author":"Cornely","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1093\/ofid\/ofw172.1280","article-title":"Breakthrough invasive fungal infections in patients with hematologic malignancy and hematopoietic cell transplantation receiving isavuconazole for empiric or directed antifungal therapy","volume":"3","author":"Dadwal","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Lionakis, M.S., Lewis, R.E., and Kontoyiannis, D.P. (2018). Breakthrough invasive mold infections in the hematology patient: Current concepts and future directions. Clin. Infect. Dis.","DOI":"10.1093\/cid\/ciy473"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1093\/cid\/cir885","article-title":"Combination therapy for mucormycosis: Why, what, and how?","volume":"54","author":"Spellberg","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1128\/AAC.49.2.721-727.2005","article-title":"Caspofungin inhibits Rhizopus oryzae 1,3-beta-d-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis","volume":"49","author":"Ibrahim","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1128\/AAC.01458-07","article-title":"Combination echinocandin-polyene treatment of murine mucormycosis","volume":"52","author":"Ibrahim","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1086\/589305","article-title":"Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against aspergillus and non-aspergillus hyphae","volume":"198","author":"Lamaris","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/17476348.2017.1325322","article-title":"Combination therapy for the treatment of pulmonary mold infections","volume":"11","author":"Petraitis","year":"2017","journal-title":"Expert. Rev. Respir. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1086\/589857","article-title":"Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis","volume":"47","author":"Reed","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/jac\/dkw433","article-title":"Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis","volume":"72","author":"Gebremariam","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"811e1","DOI":"10.1016\/j.cmi.2016.03.029","article-title":"Initial use of combination treatment does not impact early survival of 106 patients with hematologic malignancies and mucormycosis: A propensity score analysis","volume":"22","author":"Kyvernitakis","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jac\/dkn005","article-title":"In vitro activities of combinations of amphotericin B, posaconazole and four other agents against Rhizopus","volume":"61","author":"Ballester","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1128\/AAC.00628-08","article-title":"Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae","volume":"52","author":"Serena","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.mmcr.2017.05.004","article-title":"Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient","volume":"17","author":"Anderson","year":"2017","journal-title":"Med. Mycol. Case Rep."},{"key":"ref_81","first-page":"77","article-title":"Isolated renal mucormycosis","volume":"65","author":"Sriranga","year":"2017","journal-title":"J. Assoc. Physicians India"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"484","DOI":"10.12659\/AJCR.898480","article-title":"Therapeutic challenges of hepatic mucormycosis in hematologic malignancy: A case report and review of the literature","volume":"17","author":"Bernardo","year":"2016","journal-title":"Am. J. Case Rep."},{"key":"ref_83","first-page":"96","article-title":"Disseminated mucormycosis with cerebral involvement owing to Rhizopus Microsporus in a kidney recipient treated with combined liposomal amphotericin B and posaconazole therapy","volume":"14","author":"Ville","year":"2016","journal-title":"Exp. Clin. Transplant."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Harrasser, N., Banke, I.J., Hauschild, M., Lenze, U., Prodinger, P.M., Toepfer, A., Peschel, C., von Eisenhart-rothe, R., Ringshausen, I., and Verbeek, M. (2014). Clinical challenge: Fatal mucormycotic osteomyelitis caused by Rhizopus microsporus despite aggressive multimodal treatment. BMC. Infect. Dis., 14.","DOI":"10.1186\/1471-2334-14-488"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1399-3062.2009.00484.x","article-title":"Disseminated Rhizopus microsporus infection cured by salvage allogeneic hematopoietic stem cell transplantation, antifungal combination therapy, and surgical resection","volume":"12","author":"Lebeau","year":"2010","journal-title":"Transpl. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.3324\/haematol.2012.083063","article-title":"Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPE registries","volume":"98","author":"Pagano","year":"2013","journal-title":"Haematologica"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/archinte.159.12.1301","article-title":"Pulmonary mucormycosis: The last 30 years","volume":"159","author":"Lee","year":"1999","journal-title":"Arch. Intern. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/0003-4975(94)90243-7","article-title":"Pulmonary mucormycosis: Results of medical and surgical therapy","volume":"57","author":"Tedder","year":"1994","journal-title":"Ann. Thorac. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.idc.2006.06.003","article-title":"Invasive zygomycosis: Update on pathogenesis, clinical manifestations, and management","volume":"20","author":"Kontoyiannis","year":"2006","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/jac\/dkv198","article-title":"Invasive mould sinusitis in patients with haematological malignancies: A 10 year single-centre study","volume":"70","author":"Davoudi","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.idc.2015.10.011","article-title":"Mucormycoses","volume":"30","author":"Farmakiotis","year":"2016","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/MOO.0000000000000048","article-title":"Treatment outcomes in acute invasive fungal rhinosinusitis","volume":"22","author":"Zuniga","year":"2014","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1001\/archotol.124.5.520","article-title":"An approach to fulminant invasive fungal rhinosinusitis in the immunocompromised host","volume":"124","author":"Gillespie","year":"1998","journal-title":"Arch. Otolaryngol.-Head Neck Surg."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.otohns.2010.08.017","article-title":"Acute invasive fungal rhinosinusitis: Evaluation of 26 patients treated with endonasal or open surgical procedures","volume":"143","author":"Kasapoglu","year":"2010","journal-title":"Otolaryngol.-Head Neck Surg."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/lary.23912","article-title":"Survival outcomes in acute invasive fungal sinusitis: A systematic review and quantitative synthesis of published evidence","volume":"123","author":"Turner","year":"2013","journal-title":"Laryngoscope"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/1469-0691.12408","article-title":"Local control of rhino-orbito-cerebral mucormycosis dramatically impacts survival","volume":"20","author":"Vironneau","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1172\/JCI82744","article-title":"Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis","volume":"126","author":"Gebremariam","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1172\/JCI32338","article-title":"The iron helator deferasirox protects mice from mucormycosis through iron starvation","volume":"117","author":"Ibrahim","year":"2007","journal-title":"J. Clin. Investig."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/jac\/dkr375","article-title":"The deferasirox-ambisome therapy for mucormycosis (DEFEAT Mucor) study: A randomized, double-blinded, placebo-controlled trial","volume":"67","author":"Spellberg","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1469-0691.2009.02986.x","article-title":"Hyperbaric oxygen therapy and other adjunctive treatments for zygomycosis","volume":"15","author":"Tragiannidis","year":"2009","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1093\/clinids\/10.3.551","article-title":"Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis","volume":"10","author":"Ferguson","year":"1988","journal-title":"Rev. Infect. Dis."},{"key":"ref_102","first-page":"256","article-title":"Use of hyperbaric oxygen as adjunct therapy to surgical debridement of complicated wounds","volume":"2","author":"Shafer","year":"1993","journal-title":"Semin. Perioper. Nurs."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1288\/00005537-198005000-00002","article-title":"Hyperbaric oxygen in the treatment of rhinocerebral mucormycosis","volume":"90","author":"Price","year":"1980","journal-title":"Laryngoscope"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/01376517-199506000-00006","article-title":"Hyperbaric oxygen therapy for rhinocerebral fungal infection","volume":"27","year":"1995","journal-title":"J. Neurosci. Nurs."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1001\/archotol.1988.01860190095032","article-title":"Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy","volume":"114","author":"Couch","year":"1988","journal-title":"Arch. Otolaryngol. Head Neck Surg."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1128\/AAC.45.12.3601-3602.2001","article-title":"Hyperbaric oxygen as an adjunct in zygomycosis: Randomized controlled trial in a murine model","volume":"45","author":"Barratt","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1469-0691.2005.01170.x","article-title":"Hyperbaric oxygen as an adjunctive treatment for zygomycosis","volume":"11","author":"John","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/01.inf.0000134314.65398.bf","article-title":"Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children","volume":"23","author":"Abzug","year":"2004","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/428503","article-title":"Interferon-gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes","volume":"191","author":"Simitsopoulou","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1086\/317943","article-title":"Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases","volume":"183","author":"Hubel","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1128\/AAC.50.1.96-103.2006","article-title":"Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole","volume":"50","author":"Chamilos","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/infdis\/jiw090","article-title":"Statin concentrations below the minimum inhibitory concentration attenuate the virulence of Rhizopus oryzae","volume":"214","author":"Bellanger","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S1473-3099(16)30541-2","article-title":"Nivolumab plus interferon-\u03b3 in the treatment of intractable mucormycosis","volume":"17","author":"Grimaldi","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.diagmicrobio.2012.08.009","article-title":"Successful salvage therapy of refractory HIV-related cryptococcal meningitis with the combination of liposomal amphotericin B, voriconazole, and recombinant interferon-\u03b3","volume":"74","author":"Gamaletsou","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.immuni.2016.04.022","article-title":"Costimulatory and coinhibitory receptor pathways in infectious disease","volume":"44","author":"Attanasio","year":"2016","journal-title":"Immunity"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13693780701639546","article-title":"The use of 18F-fluorodeoxyglucose positron emission tomography for the diagnosis and management of invasive mould infections","volume":"46","author":"Chamilos","year":"2008","journal-title":"Med. Mycol."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Ma, L.J., Ibrahim, A.S., Skory, C., Grabherr, M.G., Burger, G., Butler, M., Elias, M., Idnurm, A., Lang, B.F., and Sone, T. (2009). Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet., 5.","DOI":"10.1371\/journal.pgen.1000549"},{"key":"ref_118","unstructured":"Fothergill, A.W., Mc Carthy, D.I., Sutton, D.A., Garvey, E.P., Hoekstra, W.J., Moore, W.R., Schotzinger, R.J., and Wiederhold, N.P. (2014, January 5\u20139). The fungal Cyp51 inhibitor VT-1161 demonstrates in vitro synergy with tacrolimus against Aspergillus spp. and members of the order Mucorales. Abstract M-1201. Proceedings of the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, USA."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7815","DOI":"10.1128\/AAC.01437-15","article-title":"VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection","volume":"59","author":"Gebremariam","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e00390-17","DOI":"10.1128\/AAC.00390-17","article-title":"Prophylactic treatment with VT-1161 protects immunosuppressed mice from Rhizopus arrhizus var. arrhizus infection","volume":"61","author":"Gebremariam","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"4652","DOI":"10.1128\/AAC.00291-11","article-title":"In vitro activity of E1210, a novel antifungal, against clinically important yeasts and molds","volume":"55","author":"Miyazaki","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"S475","DOI":"10.1093\/ofid\/ofx163.1217","article-title":"APX001A protects immunosuppressed mice from Rhizopus delemar infection. Abstract 1521","volume":"4","author":"Gebremariam","year":"2017","journal-title":"Open Forum Infect. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1093\/jac\/dkv446","article-title":"Identification and characterization of haemofungin, a novel antifungal compound that inhibits the final step of haem biosynthesis","volume":"71","author":"Rivkin","year":"2016","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Journal of Fungi"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2309-608X\/4\/3\/90\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:15:38Z","timestamp":1760195738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2309-608X\/4\/3\/90"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,31]]},"references-count":123,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,9]]}},"alternative-id":["jof4030090"],"URL":"https:\/\/doi.org\/10.3390\/jof4030090","relation":{},"ISSN":["2309-608X"],"issn-type":[{"value":"2309-608X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,31]]}}}